- Home
- ROIV vs HMY Comparison
ROIV vs HMY Comparison
Compare ROIV & HMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | HMY |
|---|---|---|
| Founded | 2014 | 1950 |
| Country | United Kingdom | South Africa |
| Employees | N/A | 34350 |
| Industry | Biotechnology: Pharmaceutical Preparations | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.7B | 12.7B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | ROIV | HMY |
|---|---|---|
| Price | $26.46 | $14.19 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 2 |
| Target Price | ★ $27.56 | $16.00 |
| AVG Volume (30 Days) | ★ 4.6M | 4.6M |
| Earning Date | 02-06-2026 | 02-04-2016 |
| Dividend Yield | N/A | ★ 1.16% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $29,053,000.00 | N/A |
| Revenue This Year | N/A | $40.34 |
| Revenue Next Year | $594.84 | $22.08 |
| P/E Ratio | ★ N/A | $15.60 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.73 | $12.57 |
| 52 Week High | $30.33 | $26.04 |
Technical Indicators
Market Signals| Indicator | ROIV | HMY |
|---|---|---|
| Relative Strength Index (RSI) | 42.18 | 33.93 |
| Support Level | $20.46 | $13.53 |
| Resistance Level | $27.94 | $15.65 |
| Average True Range (ATR) | 0.88 | 0.65 |
| MACD | -0.38 | -0.03 |
| Stochastic Oscillator | 11.63 | 28.54 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About HMY Harmony Gold Mining Company Limited
Harmony Gold Mining Co Ltd is engaged in gold mining and related activities, including exploration, extraction, and processing. The group's primary product is gold bullion, produced at operations in South Africa and Papua New Guinea. Gold byproducts include uranium and silver. Strategic projects such as the Wafi-Golpu Project in the New Guinea Mobile Belt, the Eva Copper Project in the Mt Isa Inlier, Queensland, Australia, and the MAC Copper acquisition position the company as a gold-copper producer. The company operates across South Africa, Papua New Guinea, and Australia.